NASDAQ
14 hours, 35 minutes ago 
WW
Ww International, INC
8-K: WW International Faces Delisting from Nasdaq Amid Chapter 11 Proceedings
WW International (Weight Watchers) receives notice of delisting from Nasdaq following the commencement of voluntary prepackaged Chapter 11 cases.
Worse than expected
 
NASDAQ
3 days, 1 hours ago 
WW
Ww International, INC
8-K: WW International Files for Chapter 11 to Restructure Debt, Aims for Quick Exit
WW International, Inc. initiates a pre-packaged Chapter 11 reorganization to eliminate $1.15 billion in debt and enhance its financial flexibility.
NASDAQ
3 days, 15 hours ago 
WW
Ww International, INC
10-Q: WW International Faces Debt Restructuring Amidst Financial Challenges
WW International is in discussions to restructure its debt and anticipates a prepackaged bankruptcy filing due to financial difficulties and an expected event of default.
Worse than expected
 
NASDAQ
3 days, 15 hours ago 
WW
Ww International, INC
8-K: WW International Announces Q1 2025 Results, Clinical Subscriptions Surge Amid Debt Restructuring
WW International reports a 9.7% revenue decrease in Q1 2025, but sees a 57.1% increase in clinical subscription revenues and is engaged in discussions for a plan of reorganization to significantly reduce debt.
Worse than expected
 
NASDAQ
18 days, 15 hours ago 
WW
Ww International, INC
DEF: WW International Sets Date for 2025 Annual Shareholder Meeting, Outlines Key Proposals
WW International announces its 2025 Annual Meeting of Shareholders to be held virtually on June 6, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.
NASDAQ
21 days, 15 hours ago 
WW
Ww International, INC
Form 4: WW International Executive Michael Amsel Awarded Restricted Stock Units
Chief Marketing Officer Michael Amsel receives 524,109 restricted stock units in WW International, Inc.
NASDAQ
39 days, 15 hours ago 
WW
Ww International, INC
Form 4: WW International CEO Tara Comonte Reports Stock Transactions
Tara Comonte, President and CEO of WW International, reports the acquisition and disposal of common stock and restricted stock units on March 27, 2025.
NASDAQ
49 days, 15 hours ago 
WW
Ww International, INC
8-K: WW International Faces Nasdaq Delisting Notice After Share Price Drops Below $1.00
WW International (WeightWatchers) received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.
Worse than expected
 
NASDAQ
67 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International CEO Tara Comonte Reports Stock Transactions
Tara Comonte, President and CEO of WW International, reports the acquisition and disposal of common stock and restricted stock units on February 27, 2025.
NASDAQ
70 days, 23 hours ago 
WW
Ww International, INC
10-K: WW International Reports Fiscal Year 2024 Results: Transformation Efforts Continue Amidst Market Challenges
WW International faces revenue decline due to shifts in consumer behavior and increased competition, but focuses on strategic initiatives and cost management.
Worse than expected
 
NASDAQ
71 days, 14 hours ago 
WW
Ww International, INC
8-K: WW International Announces Mixed Q4 and Full Year 2024 Results; Names Tara Comonte Permanent CEO
WW International reports a decrease in overall subscribers and revenue for Q4 and full year 2024, but sees growth in its clinical subscription business and improved margins.
Worse than expected
 
NASDAQ
95 days, 14 hours ago 
WW
Ww International, INC
8-K: WW International Borrows $121.3 Million Under Revolving Credit Facility
WW International draws down the remaining available amount under its senior secured revolving credit facility to enhance financial flexibility.
Worse than expected
 
NASDAQ
100 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Interim CEO Tara Comonte Reports Stock Transactions
Tara Comonte, Interim President and CEO of WW International, reports the acquisition and disposal of common stock and restricted stock units on January 27, 2025.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director William H. Shrank Acquires Deferred Stock Units
Director William H. Shrank acquired 3,696 deferred stock units in WW International, Inc. on December 30, 2024.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director Acquires Shares Subject to Transfer Restrictions
Tracey D. Brown, a director at WW International, acquired 3,696 shares of common stock subject to transfer restrictions on December 30, 2024.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director Steven Altschuler Reports Acquisition of Deferred Stock Units
Director Steven Altschuler reported the acquisition of 3,696 deferred stock units in WW International, Inc. on December 30, 2024.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director Julie J. Rice Acquires Shares
Julie J. Rice, a director at WW International, acquired 3,696 shares of common stock on December 30, 2024.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: Thilo Semmelbauer Reports Acquisition of Deferred Stock Units in WW International, Inc.
Director Thilo Semmelbauer acquired 3,696 deferred stock units in WW International, Inc. on December 30, 2024, according to a Form 4 filing.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director Julie Bornstein Acquires Shares
Director Julie Bornstein acquired 3,696 shares of WW International, Inc. common stock on December 30, 2024.
NASDAQ
127 days, 14 hours ago 
WW
Ww International, INC
Form 4: WW International Director Denis F. Kelly Acquires Deferred Stock Units
Director Denis F. Kelly acquired 3,696 deferred stock units of WW International, Inc. on December 30, 2024.
WW 
Ww International, INC 
NASDAQ

8-K: WW International Announces Mixed Q4 and Full Year 2024 Results; Names Tara Comonte Permanent CEO

Sentiment:
 Earnings Release
 27 February 2025 4:01 PM

WW International reports a decrease in overall subscribers and revenue for Q4 and full year 2024, but sees growth in its clinical subscription business and improved margins.

Worse than expected
  Overall subscriber numbers and total revenues decreased in both Q4 and full year 2024.  Digital and Workshops + Digital businesses experienced declines in subscribers and paid weeks.  The company reported a significant operating loss for the full year, driven by non-cash impairment charges. 

Summary
  • WW International, Inc. announced its Q4 and full year fiscal 2024 results, with the Board of Directors appointing Tara Comonte as the permanent President and CEO, effective February 26, 2025.
  • Total end-of-period subscribers were 3.3 million, a 12.2% decrease compared to the prior year, while clinical subscribers increased by 37.8% to 92,000.
  • Q4 revenues totaled $184.4 million, a 10.5% decrease year-over-year, while subscription revenues decreased by 7.3% to $181.7 million.
  • Clinical subscription revenues increased by 57.9% to $20.5 million.
  • The gross margin for Q4 was 69.7%, up 906 basis points compared to the prior year.
  • Operating income for Q4 was $36.2 million, with an operating income margin of 19.6%.
  • Net income for Q4 was $25.1 million.
  • Full year revenues were $785.9 million, a 11.6% decrease compared to the prior year.
  • The company reported a full year operating loss of $236.2 million, including $315.0 million in non-cash impairment charges.
  • The company is not providing full year fiscal 2025 guidance at this time.
  • The company aims to achieve $100 million run-rate cost savings target by the end of 2025.
Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are positives like the growth in the clinical business and improved margins, the overall decline in subscribers and revenue, along with the significant operating loss, temper the positive aspects. The lack of full year guidance also adds uncertainty.

Highlights
  • Tara Comonte has been appointed as the permanent President and CEO of WW International, effective February 26, 2025.
  • End of Period Clinical Subscribers increased 37.8% to 92,000 in Q4 2024.
  • Clinical Subscription Revenues increased 57.9% to $20.5 million in Q4 2024.
  • Q4 2024 Adjusted EBITDAS margin was 27.4%, the highest since Q3 2022.
  • Full year Clinical Paid Weeks increased 164.1%.
  • The company is targeting $100 million in run-rate cost savings by the end of 2025.
  • Gross Margin of 69.7%, up 906 basis points vs. prior year period; Adjusted Gross Margin of 69.1%, up 771 basis points vs. prior year period
Positives
  • Appointment of a permanent CEO provides leadership stability.
  • Significant growth in the clinical subscription business indicates a successful expansion into the medical weight management market.
  • Improved gross and adjusted EBITDAS margins demonstrate effective cost management.
  • Strategic cost management drove year-over-year improvement in Q424 Adjusted EBITDAS.
  • The company is on track to achieve its $100 million run-rate cost savings target by the end of 2025.
Negatives
  • Overall subscriber numbers and total revenues decreased in both Q4 and full year 2024.
  • Digital and Workshops + Digital businesses experienced declines in subscribers and paid weeks.
  • The company reported a significant operating loss for the full year, driven by non-cash impairment charges.
  • Other Revenues decreased significantly due to the closure of the consumer products business.
  • The company is not providing full year fiscal 2025 guidance at this time.
Risks
  • Competition from other weight management and health and wellness industry participants.
  • Failure to retain and grow the subscriber base.
  • Inability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market.
  • Failure to develop new, innovative services and products or enhance existing services and products.
  • Regulatory, reputational and other risks associated with the Companys new compounded GLP-1 offering.
  • Uncertainties related to a downturn in general economic conditions or consumer confidence.
  • Impact of the Companys substantial amount of debt, debt service obligations and debt covenants, and its exposure to variable rate indebtedness.
Future Outlook

The company is not providing full year fiscal 2025 guidance at this time but is focused on strengthening its financial foundation and balancing investment in growth with its capital structure.

Management Comments
  • Tara Comonte, President and CEO, stated that the company is pleased with the momentum in the Clinical business and is focused on delivering the right solutions at the right time.
  • Felicia DellaFortuna, CFO, mentioned the company's disciplined and strategic cost management, which drove year-over-year improvement in Q424 Adjusted EBITDAS and keeps the company on track to achieve its $100 million run-rate cost savings target by the end of 2025.
Industry Context

The announcement reflects the ongoing shift in the weight management industry towards comprehensive solutions, including clinical care and medication, as well as the increasing importance of digital platforms and community support. WW International is positioning itself to capitalize on these trends, but faces competition from other established players and emerging startups.

Comparison to Industry Standards
  • WW International's performance can be compared to other weight management companies like Nutrisystem, Jenny Craig, and digital health platforms such as Noom.
  • The growth in clinical subscriptions aligns with the increasing adoption of GLP-1 medications for weight loss, similar to trends observed in companies like Ro and Hims & Hers.
  • The focus on cost management and margin improvement is a common theme among companies in the health and wellness sector, as they navigate competitive pressures and changing consumer preferences.
  • WW International's adjusted EBITDAS margin of 27.4% in Q4 2024 is a key metric to benchmark against industry peers to assess its profitability and operational efficiency.
Stakeholder Impact
  • Shareholders: The mixed results and lack of full year guidance may create uncertainty for investors.
  • Employees: The appointment of a permanent CEO provides stability, while cost-saving initiatives may impact staffing.
  • Customers: Continued investment in innovative services and products aims to improve customer experience and outcomes.
  • Suppliers: Cost management efforts may impact supplier relationships and pricing.
  • Creditors: The company's debt levels and ability to generate cash to service debt remain a key concern.
Next Steps
  • Company management will discuss the fourth quarter and full year fiscal 2024 results and answer questions from the investment community during a conference call today at 5:00 p.m. ET.
  • The company will continue to focus on strengthening its financial foundation and balancing investment in growth with its capital structure.
  • The company will continue to execute on its $100 million run-rate cost savings target by the end of 2025.
Key Dates
  • 1963: WeightWatchers was founded.
  • December 30, 2023: End of fiscal year 2023.
  • February 26, 2025: Tara Comonte appointed as permanent President and CEO.
  • February 27, 2025: Date of the earnings release and conference call.
  • December 28, 2024: End of fiscal year 2024.
Keywords
WW 
Ww International, INC 
NASDAQ
Sector: TBD
 
Filings with Classifications
Worse than expected
9 May 2025 5:03 PM
8-K Filing
  • The company received a delisting notice from Nasdaq.
  • The company has commenced voluntary prepackaged cases under chapter 11 of title 11 of the United States Code.
  • Trading of WW International's common stock is expected to be suspended on May 16, 2025.
Worse than expected
6 May 2025 4:13 PM
Quarterly Report
  • The company's financial results were worse than expected due to declining revenues and increasing losses.
  • The company's leverage ratio was worse than required by its debt covenants, leading to an expected event of default.
  • The company's outlook is worse than expected due to the anticipation of a bankruptcy filing.
Worse than expected
6 May 2025 4:03 PM
Earnings Release
  • Overall revenues decreased by 9.7% year-over-year, indicating a decline in the core business.
  • Total subscribers decreased by 14.2% year-over-year, suggesting challenges in retaining and attracting customers.
  • The company is planning a prepackaged filing under Chapter 11 of the U.S. Bankruptcy Code, indicating financial distress.
Worse than expected
21 March 2025 4:05 PM
8-K Filing
  • WW International received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, which is worse than expected.
Worse than expected
28 February 2025 7:14 AM
Annual Results
  • The company's revenue decreased by 11.6% compared to the previous year.
  • The company recorded a net loss of $345.7 million, a significant increase from the net loss of $112.3 million in the previous year.
  • The company's operating loss was $236.2 million, compared to an operating income of $22.3 million in the previous year.
Worse than expected
27 February 2025 4:01 PM
Earnings Release
  • Overall subscriber numbers and total revenues decreased in both Q4 and full year 2024.
  • Digital and Workshops + Digital businesses experienced declines in subscribers and paid weeks.
  • The company reported a significant operating loss for the full year, driven by non-cash impairment charges.
Worse than expected
3 February 2025 4:15 PM
8-K Filing
  • The company needed to draw down the remaining amount of its revolving credit facility, which may indicate financial strain.
Worse than expected
6 November 2024 4:03 PM
Quarterly Report
  • The company's Q3 2024 results were worse than expected due to a significant net loss, a decline in revenue, and substantial impairment charges.
  • The company's net loss for the first nine months of 2024 was significantly worse than the same period in 2023 due to a large impairment charge.
Worse than expected
6 November 2024 7:05 AM
Quarterly Report
  • The company's revenue and overall subscriber numbers were down compared to the prior year, indicating worse than expected results.
Worse than expected
1 August 2024 7:13 AM
Quarterly Report
  • The company's revenue declined by 10.9% in the second quarter and 12.8% for the first six months of 2024, indicating worse than expected performance.
  • The company recorded a significant net loss of $324.6 million for the first six months of 2024, primarily due to a large impairment charge, which is worse than expected.
Worse than expected
1 August 2024 7:05 AM
Quarterly Report
  • The company's revenue decreased by 10.9% year-over-year, indicating worse than expected performance.
  • The company's net income decreased by 54.2% year-over-year, indicating worse than expected performance.
  • The company's total end of period subscribers decreased by 6.1% year-over-year, indicating worse than expected performance.
Worse than expected
24 May 2024 5:15 PM
Amendment to 8-K Filing
  • The proposal to adopt a majority voting standard for uncontested director elections was not approved by shareholders, which is a negative outcome for the company's governance structure.
  • The initial voting results were erroneous, requiring a correction, which reflects poorly on the company's internal processes.
Worse than expected
9 May 2024 5:39 PM
Quarterly Report Amendment
  • The company's net loss of $347.9 million is significantly worse than the $118.7 million loss in the same period last year.
  • The company's revenue decreased by 14.6%, indicating a worse performance compared to the prior year.
  • The company's operating loss of $269.3 million is significantly worse than the $28.6 million loss in the prior year.
Worse than expected
9 May 2024 4:30 PM
Quarterly Report Amendment
  • The company's revenue decreased by 14.6% year-over-year, indicating a worse performance than expected.
  • The company reported a significant operating loss of $269.3 million, primarily due to non-cash impairment charges, which is worse than expected.
  • The company's total end of period subscribers decreased by 0.5% year-over-year, indicating a worse performance than expected.
Worse than expected
2 May 2024 4:09 PM
Quarterly Report
  • The company's net loss of $347.9 million is significantly worse than the $118.7 million loss in the same quarter last year.
  • The company's revenue decreased by 14.6%, indicating a decline in business performance.
  • The company incurred a $258 million impairment charge on franchise rights, further impacting the financial results.
Worse than expected
2 May 2024 4:05 PM
Quarterly Report
  • The company reported a significant operating loss of $269.3 million, primarily due to non-cash impairment charges, which is worse than expected.
  • Subscription revenues decreased by 3.7% on a constant currency basis, indicating a decline in core business performance.
  • Other revenues declined dramatically by 92.0% on a constant currency basis, which is a significant negative impact.
Better than expected
14 March 2024 4:41 PM
Regulation FD Disclosure
  • The company is on track to exceed its previously provided guidance for clinical subscribers, indicating better than expected performance.
Worse than expected
28 February 2024 4:29 PM
Annual Results
  • The company's revenue decreased by 14.5% year-over-year, indicating worse than expected performance.
  • The company's gross profit decreased by 14.8% year-over-year, indicating worse than expected performance.
  • The company's operating income margin decreased by 4.6% year-over-year, indicating worse than expected performance.
Worse than expected
28 February 2024 4:06 PM
Quarterly Report
  • The company's revenue decreased by 7.6% in Q4 2023 and 14.5% for the full year 2023, indicating worse than expected performance.
  • The company reported a net loss of $88.1 million in Q4 2023 and $112.3 million for the full year 2023, which is worse than the prior year.

Disclaimer: This summary was generated by artificial intelligence and its accuracy is not guaranteed. The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.